We have measured the forces that act on the electrode-bearing surface of an intradural neuromodulator designed to be in direct contact with the pial surface of the spinal cord, as part of our effort to develop a new method for treating intractable pain. The goal was to investigate the pressures produced by this device on the spinal cord and compare them with normal intrathecal pressure. For this purpose, we employed a dual-sensor arrangement that allowed us to measure the response of a custom-designed silicone spinal cord surrogate to the forces applied by the device. We found that the device had a mean compliance of %63 lN lm
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, and that over a 3 mm range of compression, the mid-span pressure it exerted on the spinal cord was %1.88 Â 10 3 Pa ¼ 14.1 mm Hg, which lies within the range of normal intrathecal pressure in humans. 1 We are developing the human spinal cord modulation system (HSCMS) as a new approach to this method of treating intractable pain.
2 Our goal is to design an intradural implant with an electrode array that can be placed directly on the pial surface of the spinal cord. The intent is to generate therapeutic levels of current density within specific neuronal pathways in the dorsal columns, while avoiding stimulation of non-targeted structures such as the dorsal nerve rootlets. Such optimization of nerve-fiber targeting can be difficult to achieve with standard epidural stimulators, because the fields produced by those devices are subject to dissipative shunting by the relatively high conductivity ($1.7 S m À1 ) cerebrospinal fluid (CSF) surrounding the spinal cord. 3 The result is that only fibers in a layer $250 lm deep in the spinal cord can be excited 4 within an acceptable therapeutic window of stimulus signal strength, hence up to half of all patients with epidural stimulators receive limited pain relief. 5 By placing the electrode array directly on the pial surface of the spinal cord, we seek to minimize shunting by the CSF while maximizing the positional stability of the electrodes.
Figure 1(a) illustrates the device designed for this purpose and Fig. 1(b) is a photograph of an early prototype. In our intradural arrangement, the electrode-bearing membrane is placed directly on the dorsal surface of the spinal cord via surgical laminectomy and durotomy, with the dura then re-sealed via a leak-free dural cuff. The membrane is kept in place on the dorsal surface by the forces exerted on it by the loop-shaped lead assembly, the upper side of which makes contact with the attachment arm that helps position and secure the dural closure, and which also provides stress relief for the exiting cable that is composed of the individual leads. The electrode-bearing surface of the device pictured in Fig. 1(b) is 7 mm Â 7.1 mm, for a surface area of approximately 50 mm
. It is $ 0.6 mm thick. For comparison, the titanium positioning strap is 30 mm Â 6.5 mm. The device shown here has six electrodes in a 3 Â 2 matrix in the membrane, with one lead per electrode. The leads are of insulated 0.1 mm diameter nanograin damage resistant wire, shaped into arcs with three to the left and three to the right, thus, forming a closed loop that separates the top of the leadbearing membrane from the bottom of the titanium mounting strap by about 6.5 mm.
Our original conception 2 of the HSCMS called for it to be a wireless device. 6 While a desirable long-term option, the wireless approach is not critical for initiation of pilot trials in patients, so the wired device shown in Fig. 1 is instead being used in our in vitro and in vivo studies aimed at investigating the safety and efficacy of the HSCMS.
An important concern is understanding the interaction between the electrode-bearing surface of the device and the pial surface of the spinal cord. The mechanics of contact between the implant and the spinal cord are complex and must be explored thoroughly, as the device is meant to be in place permanently. Our initial in vivo studies in an ovine model 7 tested various fixation approaches which eventually led to the device shown in Fig. 1 .
In particular, it became clear that the electrode-bearing surface of the device must remain in continuous contact with the dorsal surface of the spinal cord while the cord moves in the anterior-posterior (front-back) and rostral-caudal (up-down) directions during normal patient activity. If the device does not remain in contact with the spinal cord, the therapeutic stimuli will not be delivered properly. However, the pressure applied by the device must not be so large as to a) Author to whom correspondence should be addressed. Electronic mail: matthew-howard@uiowa.edu. (2013) restrict flow in the surface blood vessels or cause any type of tissue injury. The front-back motions are typically of millimeter scale 8 (although the CSF-filled gap between the dura and cord can be several mm wide 9 ), while the up-down motions can be up to 1 cm. 10 The mechanical restoring force at work during compression and expansion of the lead loop with cord motion produces the gentle dynamic pressure that maintains the required contact between the device and the spinal cord. Our goal in the present study was to measure the range of pressures exerted by the device on the spinal cord and compare them against normal physiological intrathecal pressures (ITPs) in order to validate these design principles.
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The experimental arrangement is shown in Fig. 2 . The HSCMS prototype was fixed to the bottom of a 15 cm length of 9 gauge (4.2 mm OD) stainless steel tube, with the HSCMS leads passed inside the tube for protection during handling. The upper end of the tube was threaded onto the plunger of an Ametek-Chatillon model SLC-250 G load cell read by a model DFS force gauge (resolution ¼ 500 lN). The load cell was fixed to a micrometer-driven translation stage (resolution ¼ 25 lm), which was secured to vertical stand-offs on an optical table. The HSCMS membrane was then placed in contact with the dorsal surface of a silicone model of the spinal cord, specially designed to have biomechanical characteristics that mimic those of the actual tissues. 11, 12 It matched the general shape of the mid-thoracic spinal cord in humans. 13 Because the forces to be measured would be very small, we incorporated a second sensor in order to provide independent verification of the results and to help uncover any systematic uncertainties. Toward that end, the working surface on which the surrogate spinal cord was placed was the pan of a Denver Instruments Co. model TR-403 digital scale (resolution ¼ 1 mg, i.e., %10 lN). Equal and opposite forces would thus be sensed by the load cell above the HSCMS and the scale below it. Following separate calibrations of both instruments using the same proof masses, the electrode-bearing surface was lowered onto the top of the spinal cord surrogate. The force-gauge and scale readings were then recorded as the micrometer compressed the lead loop in 25 lm increments, thus, applying slowly increasing pressure over the area of contact between the electrode-bearing surface of the HSCMS and the underlying dorsal layer of the surrogate. Data were taken over a compression range of $3 mm, which is roughly double the anterior-posterior movement span of the spinal cord in the thoracic region. Three trials were run for each of the three HSCMS prototypes that were tested.
The raw data from one of the runs with this dual-sensor measurement scheme are plotted in Fig. 3(a) . The other results were virtually identical, with all of them showing <2% departure between the restoring force as measured with the force gauge vs. the scale over the full compression range. A secondorder fit to the curved part of the plot (i.e., for compressions >250 lm) yielded R 2 ¼ 0.999, thus, confirming that the system behaved as expected, viz., like a soft torsion spring with a nonlinear response. The mid-range (1500 lm) value of the restoring force was 63 lN lm surrogate spinal cord is plotted as a function of compressive displacement in Fig. 3(b) , with the mid-range value of pressure being %1880 Pa (¼14.1 mm Hg). The shaded region in Fig. 3(b) corresponds to the approximate range of normal intrathecal and intracranial pressure of the CSF within the subdural compartment. 14, 15 (Transient and other excursions from these nominal values, e.g., due to postural changes, are well documented 16 and thus this range may vary from patient to patient.)
The results show that the pressure exerted by the HSCMS on the spinal cord will be similar to normal ITP, thus, suggesting minimal risk of tissue damage after implantation. Moreover, the maximum value of pressure measured in these experiments, %20 mm Hg, is by itself roughly 4Â less than the normal diastolic blood pressure (%80 mm Hg), and still less than half that amount when added to the nominal background value of ITP. This suggests that the blood flow through the vessels on the surface of the spinal cord should not be significantly impeded by the presence of the device. To our knowledge, there are no reports in the literature describing the threshold forces or pressures that an implanted device must exert on the spinal cord in order to produce damage. Therefore, careful investigation of the spinal cord's response to the presence of the HSCMS will still be needed in a suitable in vivo trial involving chronic implantation.
If it should turn out that lower applied pressure levels are clinically advantageous, this could be achieved by increasing the surface area of the HSCMS. We note that the surgical technique for placing the HSCMS on the spinal cord involves securing the extradural lead rigidly to the vertebrae while the patient is in a prone and flexed position during surgery, thus, insuring that the spinal cord will be in its ventral-most position at the time of implantation. This is to prevent the spinal cord from making any HSCMS-driven contact with the ventral boundary of the spinal canal. (There are centering forces exerted on the spinal cord by its dentate ligaments, but measurements of them have been limited to cadaver samples. 17 The forces in living tissues are not yet known.) Studies such as these will help to optimize the form and function of the device, but many other factors must also be considered when assessing the overall safety and efficacy of the HSCMS. Although general safety considerations including biocompatibility must be addressed with any type of chronically implanted device, some concerns will be specific to the HSCMS, for example, its behavior during movement of the spinal cord, the potential for any surface abrasion effects, and potential variations in the intensity of the stimuli delivered to the tissue, among several others. Hence much additional work will be needed. The device can only be implanted in patients for purposes of a pilot clinical trial after successful completion of a comprehensive battery of experiments that address all safety-related concerns to the satisfaction of the relevant regulatory agencies.
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